Rivaroxaban in patients with a recent acute coronary syndrome.
暂无分享,去创建一个
Paul Burton | Deepak L. Bhatt | Deepak L Bhatt | Shinya Goto | Jessica L Mega | J. Mega | E. Braunwald | S. Murphy | C. Bode | K. Fox | C. Gibson | S. Goto | F. Verheugt | S. Wiviott | J. Bassand | A. Plotnikov | Marc Cohen | Christoph Bode | Freek W A Verheugt | Sabina A Murphy | C Michael Gibson | Eugene Braunwald | Stephen D Wiviott | Keith A A Fox | P. Burton | Jean-Pierre Bassand | Marc Cohen | Nancy Cook-Bruns | Alexei N Plotnikov | David Schneider | Xiang Sun | Xiang Sun | N. Cook-Bruns | D. Schneider | C. Gibson
[1] Bruce L Davidson,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.
[2] F. Van de Werf,et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. , 2011, European heart journal.
[3] D. Ardissino,et al. Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction , 1994, Circulation.
[4] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[5] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[6] W. Weaver,et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.
[7] M. Gent,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial , 2009, The Lancet.
[8] G. Lip,et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome , 2011, European heart journal.
[9] D. Parra,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011 .
[10] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[11] E. Antman,et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.
[12] Bengt I Eriksson,et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial , 2008, The Lancet.
[13] W. Ageno,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. , 2008, The New England journal of medicine.
[14] H. Diener,et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.
[15] B. Gersh. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes , 2008 .
[16] J. Cook,et al. Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit , 2005, Annals of Internal Medicine.
[17] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[18] R. Gans,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.
[19] J. Mega,et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial , 2009, The Lancet.
[20] B. Eriksson,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. , 2008, The New England journal of medicine.
[21] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[22] Deepak L. Bhatt,et al. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial , 2009, Circulation.
[23] J. Nunnelee. Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510. , 2011, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.
[24] R. Jay. Low-molecular-weight heparin during instability in coronary artery disease , 1996, The Lancet.
[25] Deepak L. Bhatt,et al. Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.